文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA-617 对比多西他赛治疗未接受化疗的转移性去势抵抗性前列腺癌:一项随机对照 2 期非劣效性试验

177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-11-29

这项随机、平行组、开放标签、2 期非劣效性试验在未接受化疗的 mCRPC 患者中比较 177Lu-PSMA-617 与多西他赛,主要终点为最佳 PSA 缓解率。177Lu-PSMA-617 组为 60%(9/15),多西他赛组为 40%(8/20),差值 20%(95%CI:-12~47,P=0.25),符合预设非劣效标准;作者认为 177Lu-PSMA-617 安全且非劣于多西他赛,可能更早用于疾病进程。

要点

  • 未接受化疗的 mCRPC 患者中,177Lu-PSMA-617 组最佳 PSA 缓解率为 60%(9/15),多西他赛组为 40%(8/20)。
  • 两组 PSA 缓解率差值 20%(95%CI:-12~47,P=0.25),符合预设非劣效标准。
  • 177Lu-PSMA-617 组生活质量改善较多西他赛组更显著(P<0.01)。

核心结论

  • 作者认为,177Lu-PSMA-617 在 mCRPC 治疗中安全且非劣于多西他赛,因此可能更早用于疾病进程,而非仅保留用于晚期终末期疾病。

研究设计与样本

  • 这是一项随机、平行组、开放标签、2 期非劣效性试验。
  • 研究对象为未接受化疗、68Ga-PSMA-11 PET/CT 显示高 PSMA 表达病灶的 mCRPC 患者。
  • 2019 年 12 月至 2021 年 3 月期间,评估合格性的 45 例患者中有 40 例接受随机分组,按 1:1 比例分配至 177Lu-PSMA-617 组或多西他赛组。

主要发现

  • 177Lu-PSMA-617 组 20 例中 15 例、多西他赛组 20 例中 20 例按方案接受治疗。
  • 按方案分析中,177Lu-PSMA-617 组最佳 PSA 缓解率为 60%(9/15),多西他赛组为 40%(8/20)。
  • 两组 PSA 缓解率差值为 20%(95%CI:-12~47,P=0.25),符合预设的非劣效性标准。
  • 6 个月无进展生存率在 177Lu-PSMA-617 组为 30%、多西他赛组为 20%,差值 10%(95%CI:-18~38,P=0.50)。
  • 治疗中出现 ≥3 级不良事件在 177Lu-PSMA-617 组为 6/20(30%)、多西他赛组为 10/20(50%),P=0.20;177Lu-PSMA-617 组生活质量改善较多西他赛组更显著(P<0.01)。

关键数值与推荐

  • 177Lu-PSMA-617 给药方案为 6.0-7.4 GBq/周期,每 8 周一次,最多 4 个周期。
  • 多西他赛给药方案为 75 mg/m2/周期,每 3 周一次,最多 10 个周期。
  • 主要终点最佳 PSA 缓解率按 Prostate Cancer Clinical Trials Working Group-3 定义,即较基线 PSA 下降 ≥50% 的患者比例。
  • PSA 缓解率的非劣效性界值预设为 -15%。

临床怎么用

  • 作者认为,177Lu-PSMA-617 安全且非劣于多西他赛,可能更早用于 mCRPC 疾病进程,而非仅保留用于晚期终末期疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lutetium-177 prostate-specific membrane antigen-617 (177Lu-PSMA-617) in end-stage metastatic castration-resistant prostate cancer (mCRPC) has reported favourable outcomes. In this study, we aimed to prospectively compare the efficacy and safety of 177Lu-PSMA-617 and docetaxel in chemotherapy-naïve mCRPC patients. METHODS: This was a randomized, parallel-group, open-label, phase 2, and non-inferiority trial. Chemotherapy-naïve patients with mCRPC and high PSMA-expressing lesions on 68 Ga-PSMA-11 PET/CT were randomly assigned in 1:1 ratio to 177Lu-PSMA-617 (6.0-7.4 GBq/cycle, every 8 weeks, up to 4 cycles) or docetaxel (75 mg/m2/cycle, every 3 weeks, up to 10 cycles). The primary end-point was best prostate-specific antigen response rate (PSA-RR), defined according to Prostate Cancer Clinical Trials Working Group-3 as proportion of patients achieving ≥ 50% decline in PSA from baseline. Non-inferiority margin of - 15% was pre-specified for PSA-RR. RESULTS: Between December 2019 and March 2021, 40 of the 45 patients assessed for eligibility underwent randomization. Fifteen of 20 patients in 177Lu-PSMA-617 arm and 20/20 patients in docetaxel arm received treatment per protocol. Of these, best PSA-RR in the 177Lu-PSMA-617 arm was 60% (9/15) versus 40% (8/20) in the docetaxel arm. The difference in the PSA-RRs between the two arms was 20% (95% confidence interval, CI: - 12-47, P = 0.25), meeting the pre-specified criterion for non-inferiority in per-protocol analysis. Further, progression-free survival rates at 6 months were 30% and 20% in the 177Lu-PSMA-617 and docetaxel arms respectively (difference 10%, 95% CI: - 18-38, P = 0.50). Overall, treatment-emergent grade ≥ 3 adverse events occurred less frequently with 177Lu-PSMA-617 than with docetaxel (6/20, 30% versus 10/20, 50%, respectively, P = 0.20). Quality-of-life outcomes improved significantly in 177Lu-PSMA-617 arm compared to docetaxel arm (P < 0.01). CONCLUSION: 177Lu-PSMA-617 was demonstrated to be safe and non-inferior to docetaxel in the treatment of mCRPC and could, thus, be potentially employed earlier in the disease course rather than being solely reserved for advanced end-stage disease. CLINICAL TRIAL REGISTRATION: Clinical Trials Registry-India, CTRI/2019/12/022282.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Satapathy S, Mittal BR, Sood A, et al. 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging. 2021. PMID: 34842950. doi:10.1007/s00259-021-05618-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。